Zobrazeno 1 - 10
of 229
pro vyhledávání: '"Frank R. Lichtenberg"'
Autor:
Frank R. Lichtenberg
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 17, Iss 1 (2024)
Background More recently approved drugs have significantly fewer indications than drugs approved many years ago. One possible reason for this may be that, controlling for the number of years since approval or launch, more recently approved drugs have
Externí odkaz:
https://doaj.org/article/cd9ff3c7f9724e53bdcf5ccf0e3698f4
Autor:
Frank R. Lichtenberg
Publikováno v:
SSM: Population Health, Vol 24, Iss , Pp 101514- (2023)
We analyze the relationship between long-run changes in the drugs provided by the Pharmaceutical Benefits Scheme (PBS) and mortality and hospital utilization in Australia, by analyzing the correlation across diseases between the change in the number
Externí odkaz:
https://doaj.org/article/9a06e8b34c6f4f37a9c0a8b49bafd844
Autor:
Frank R. Lichtenberg
Publikováno v:
Swiss Journal of Economics and Statistics, Vol 158, Iss 1, Pp 1-24 (2022)
Abstract We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland during the period 1996–2018, and its association with hospital utilization for all diseases in Switzerland during the p
Externí odkaz:
https://doaj.org/article/1c9adc46b9174f0b90901aff4340c18f
Autor:
Frank R. Lichtenberg
Publikováno v:
East Asian Economic Review, Vol 24, Iss 2, Pp 127-164 (2020)
We perform an econometric assessment of the role that pharmaceutical innovation— the introduction and use of new drugs—has played in improving the health of Koreans, by investigating whether diseases for which more new drugs were launched had l
Externí odkaz:
https://doaj.org/article/aec9099cc84f437dab6dd49705a2285a
Autor:
Frank R. Lichtenberg
Publikováno v:
Latin American Economic Review, Vol 26, Iss 1, Pp 1-22 (2017)
Abstract I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003–2013, by investigating whether there were larger declines in the age-standardized mortality rate of cancer sites (breast, lung, col
Externí odkaz:
https://doaj.org/article/1ae8ba3232e34914a3950ca21e85c7cb
Autor:
Frank R. Lichtenberg
Publikováno v:
SSM: Population Health, Vol 8, Iss , Pp - (2019)
We perform an econometric assessment of the role that pharmaceutical innovation—the introduction and use of new drugs—has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched
Externí odkaz:
https://doaj.org/article/43e922afa7c04304af3ae8b6ba8d4101
Autor:
Frank R. Lichtenberg Ph.D.
Publikováno v:
Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 43 (2006)
Externí odkaz:
https://doaj.org/article/dcf8711fced34e00843a2e5f2356db05
Autor:
Frank R. Lichtenberg
Publikováno v:
Economics of Innovation and New Technology. :1-18
Autor:
Frank R. Lichtenberg
Publikováno v:
Journal of Evolutionary Economics. 32:1155-1173
Autor:
Frank R, Lichtenberg
Publikováno v:
Forum for Health Economics and Policy. 24:35-74
This study seeks to analyze the overall impact that biopharmaceutical innovation had on disability, Social Security recipiency, and the use of medical services of U.S. community residents during the period 1998–2015. We test the hypothesis that the